Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Hauben

Showing results (71-80 of 112) with videos related to

Pageof 12
Sort By:
Expert Opinion on Drug Safety|June 24, 2024
The evolving role of disproportionality analysis in pharmacovigilanceMichele Fusaroli, Emanuel Raschi, Elisabetta Poluzzi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 6, 2007
Association between gastric acid suppressants and Clostridium difficile colitis and community-acquired pneumonia: analysis using pharmacovigilance toolsManfred Hauben, Sebastian Horn, Lester Reich, et al.
Drug Safety|June 1, 2007
'Extreme duplication' in the US FDA Adverse Events Reporting System databaseManfred Hauben, Lester Reich, James DeMicco, et al.
Drug Safety|February 17, 2016
Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP)Manfred Hauben, Jeffrey K Aronson, Robin E Ferner
Drug Safety|January 26, 2012
Paradoxical and bidirectional drug effectsSilas W Smith, Manfred Hauben, Jeffrey K Aronson
Cutaneous and Ocular Toxicology|March 12, 2008
Drug-induced psoriasis: results from pharmacovigilance tools under investigationManfred Hauben, Lester Reich, Suzanne Magliano, et al.
Clinical Therapeutics|July 9, 2024
Knowledge Graphs in Pharmacovigilance: A Scoping ReviewManfred Hauben, Mazin Rafi, Ibrahim Abdelaziz, et al.
Pharmacoepidemiology and Drug Safety|May 7, 2021
More extreme duplication in the U.S. FDA FAERS database and a suggested check point for disproportionality analysisManfred Hauben, Chen Zou, Steve Bright, et al.
European Journal of Clinical Pharmacology|March 17, 2007
Illusions of objectivity and a recommendation for reporting data mining resultsManfred Hauben, Lester Reich, Charles M Gerrits, et al.
Pharmacoepidemiology and Drug Safety|July 20, 2007
Hepatitis B vaccination and multiple sclerosis: a data mining perspectiveManfred Hauben, Motonobu Sakaguchi, Vaishali Patadia, et al.
Pageof 12

Showing results (71-80 of 112) with videos related to

Sort By:
Pageof 12
Expert Opinion on Drug Safety|June 24, 2024
The evolving role of disproportionality analysis in pharmacovigilanceMichele Fusaroli, Emanuel Raschi, Elisabetta Poluzzi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 6, 2007
Association between gastric acid suppressants and Clostridium difficile colitis and community-acquired pneumonia: analysis using pharmacovigilance toolsManfred Hauben, Sebastian Horn, Lester Reich, et al.
Drug Safety|June 1, 2007
'Extreme duplication' in the US FDA Adverse Events Reporting System databaseManfred Hauben, Lester Reich, James DeMicco, et al.
Drug Safety|February 17, 2016
Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP)Manfred Hauben, Jeffrey K Aronson, Robin E Ferner
Drug Safety|January 26, 2012
Paradoxical and bidirectional drug effectsSilas W Smith, Manfred Hauben, Jeffrey K Aronson
Cutaneous and Ocular Toxicology|March 12, 2008
Drug-induced psoriasis: results from pharmacovigilance tools under investigationManfred Hauben, Lester Reich, Suzanne Magliano, et al.
Clinical Therapeutics|July 9, 2024
Knowledge Graphs in Pharmacovigilance: A Scoping ReviewManfred Hauben, Mazin Rafi, Ibrahim Abdelaziz, et al.
Pharmacoepidemiology and Drug Safety|May 7, 2021
More extreme duplication in the U.S. FDA FAERS database and a suggested check point for disproportionality analysisManfred Hauben, Chen Zou, Steve Bright, et al.
European Journal of Clinical Pharmacology|March 17, 2007
Illusions of objectivity and a recommendation for reporting data mining resultsManfred Hauben, Lester Reich, Charles M Gerrits, et al.
Pharmacoepidemiology and Drug Safety|July 20, 2007
Hepatitis B vaccination and multiple sclerosis: a data mining perspectiveManfred Hauben, Motonobu Sakaguchi, Vaishali Patadia, et al.
Pageof 12